Abstract
CTCs are essential for establishing metastasis in breast cancer. While many assays currently exist for the enumeration of CTCs, limitations include the reliance on the expression of the cell surface marker epithelial cell adhesion molecule (EpCAM). These approaches may omit CTCs expressing either no/low levels of EpCAM, eventually representing the metastasis-initiating population. In order to successfully capture EpCAM-negative or -low breast cancer cells we have tested different antibodies specific for surface proteins and extracellular matrix (ECM) components for cell lines, spiked samples and blood of metastatic breast cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Senologie - Zeitschrift für Mammadiagnostik und -therapie
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.